Lingohr Asset Management GmbH Has $302,000 Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Lingohr Asset Management GmbH significantly reduced its Teva Pharmaceutical stock position by 91.6%, ending the quarter with 18,000 shares valued at $302,000.
• Teva's quarterly earnings surpassed estimates, reporting $0.66 EPS on a revenue of $4.18 billion, although this was below the expected $4.34 billion.
• Various institutional investors are actively modifying their holdings, with notable increases from Ion Asset Management and Harel Insurance Investments, indicating strong interest in Teva stocks.

Lingohr Asset Management GmbH lowered its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 91.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 18,000 shares of the company's stock after selling 197,159 shares during the quarter. Lingohr Asset Management GmbH's holdings in Teva Pharmaceutical Industries were worth $302,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of TEVA. Golden State Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $39,000. New Age Alpha Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter worth $43,000. Compagnie Lombard Odier SCmA acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter worth $54,000. Banque Cantonale Vaudoise acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth about $74,000. Finally, Brooklyn Investment Group grew its position in Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock worth $77,000 after buying an additional 4,014 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Activity

In other news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded down $0.16 on Friday, hitting $18.30. The company's stock had a trading volume of 2,058,103 shares, compared to its average volume of 11,895,434. The company has a market capitalization of $20.98 billion, a PE ratio of -114.41, a PEG ratio of 1.07 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a 50 day moving average price of $17.47 and a 200 day moving average price of $16.56.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries's revenue was up .3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TEVA. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, UBS Group decreased their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.